drugset / Trial / NCT06291857
A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
RandomizedCrossoverSingle-blindPrevention
Summary
This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine. The researchers conducting the study won't know which vaccine each participant receives, ensuring their observations are unbiased. This study compares the new combination vaccine to an already available flu vaccine to see how well it works. It's a large-scale, final-stage study designed to thoroughly check how well the vaccines trigger an immune response (immunogenicity) and how safe they are.
Timeline
- Start
- 2024-12-09
- Primary completion
- 2025-12-24
- Completion
- 2026-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIC Vaccine | Vaccine | 0.5 ml | Intramuscular |
| Subject | Influenza Virus Vaccine | Vaccine | 0.5 ml | Intramuscular |
| Subject | Novavax COVID-19 vaccine | Vaccine | 0.5 ml | Intramuscular |
| Subject | tNIV Vaccine | Vaccine | 0.5 ml | Intramuscular |